Member Info for KingHomerJ

Yeah saw that very interesting - especially one coming out of Oxford

I Have - zero response to numerous now…

Sienna - NO

You really need to understand what you are investing in……… you keep referencing AI this isn’t anything new to PYC it’s the same thing they have been doing for 2 Decades

How to restore more confidence in PYC…

* More dialogue with shareholder

* Very clear coms in RNS (not leaving info out)

* Following up and updating pervious RNS

* Explain the short, medium and long term plan…route to market for products - it’s all ifs and maybes if any at all atm.

* increase social media engagements via increased followings

* keep website up to date - there is numerous errors all over it atm, for example the amount of contracts won differs and different pages.

* Respond to shareholder

* Update on Recruitment

* Publish Hiracharcy Structure to allow all shareholders, stakeholders etc understand whom does what in the organisation

* BOD buying shares obviously

* More to investor presentation to new and potential shareholders on larger platforms

I’ll say it again for the million time….the market has zero confidence and this needs to be restored…

The potential is multiples and multiples of 2p over time with more comms, updates and contracts. Never know some Directors buys may appear....???

DoseseMx is integrated into some of the biggest systems and platforms on earth !!!

DoseMe already integrated to

ILUN HEALTH- MERCK £207 Billion MC

Wolters Kluwer £24 Billion MC

Cerner £26.71 Billion MC

Strong strong update…..research basis equals data.

DoseMe has 10,000’s or customers

Research equals data

Data equals value £££

De Bull,

Sorry should have made it more clear…I wasn’t referring to the contract RNS.

Was previous RNS’s which are hazy….or the promise of updates..

Staffing….

Dr Chis IP’s what are they…

I mean you could go back as far as saying there was never an update on the VAL scientific Board updates ???

Look we all want PYC to thrive and I’m sure I will…my point is the market needs confidence and I think that’s evident to see…

We all need to be supportive but constructive and realistic at the same time

The lack of movement (As I've been saying for a while now) is the lack of confidence the market has in PYC.

The company need to resolve this....we could get another 3 contracts and we would still be under 2p....

The company in my view needs to......

* Be more informative on RNS

* More Regular RNS Updates

* Update on projects more - dosemerx / CRUK / Beyond Blood /

* Clarity on deals

* Directors Purchases

* Company presentations to investors (not investor meets company)

Must be gutted

Reading on the text at the bottom - it’s actually AstraZeneca

Funding information

This work was funded through the Biotechnology and Biosciences Research Council (BBSRC) Industrial CASE studentship in collaboration with AstraZeneca (AZ), UK.

From that paper

CRediT authorship contribution statement

David Hodson: Writing – review & editing, Conceptualization, Data curation. Hitesh Mistry: Writing – review & editing, Conceptualization, Supervision. James Yates: Writing – review & editing, Supervision, Conceptualization. Sofia Guzzetti: Writing – review & editing, Supervision. Michael Davies: Writing – review & editing, Supervision. Leon Aarons: Writing – review & editing, Supervision, Methodology. Kayode Ogungbenro: Writing – review & editing, Supervision, Funding acquisition, Conceptualization.

Other people on that paper

Sofia Guzzetti's Associate Principal Scientist · AstraZeneca

Michael Davies Principal Scientist AstraZeneca

???

Research Paper published April 2024

Hierarchical cluster analysis and nonlinear mixed-effects modelling for candidate biomarker detection in preclinical models of cancer.

https://www.researchgate.net/publication/379908059_Hierarchical_cluster_analysis_and_nonlinear_mixed-effects_modelling_for_candidate_biomarker_detection_in_preclinical_models_of_cancer

David Hodson (Full Time Employee of PYC) Dr Mistry Consultant

Dr James Yates also author….

https://scholar.google.com/citations?hl=en&user=Lv_S-dUAAAAJ&view_op=list_works&sortby=pubdate

Dr James Yates is Scientific Director, PKPD at GSK

640k Sell today by the looks of it ….

Quote

“Exscientia another AI drug discovery development company...slowly disappointing...fancy an 80% loss in 2 years ...investing in AI drug disocvery/development companies is not what its cracked up to be...”

Interesting Paul Edward’s President & CEO of Dosemerx liking the tweets

When the company or any company reference projects are on hold 99% of the time it’s awaiting funding to progress.

PYC has mentioned there are various contracts within the pipeline that are on hold…

Maybe not anymore….id have a tendency to agree with you.

Prostate App gets its approval it’s an effective route to market in Europe with DoseMe or could be ???

Https://www.businesswire.com/news/home/20240530632558/en/DoseMeRx-Submitted-a-Formal-Application-for-CE-Certification-Under-MDR-Ensuring-Uninterrupted-Service-and-Safety-for-Customers-and-Patients